Cosmo Pharmaceuticals–Sigalova S: management, 202411– CFO before Moderna + Alexion Pharmaceuticals + Vertex Pharmaceuticals

	Period	2024-11-11
	Organisation	Cosmo Pharmaceuticals N.V. (SIX: COPN)
	Group	Cosmo Pharmaceuticals (Group)
	Organisation 2	Moderna Inc. (Nasdaq: MRNA)
	Group	Moderna (Group)
	Product	MMX Multi Matrix System™ drug delivery technology
	Product 2	MedTech (medical technology)
	Person	Sigalova, Svetlana (Cosmo Pharmaceuticals 202411– CFO before Moderna + Alexion Pharmaceuticals + Vertex Pharmaceuticals)
	Person 2	Donnelly, Niall (Cosmo Pharmaceuticals 201607 CFO)

Cosmo Pharmaceuticals N.V.. (10/11/24). "Press Release: Cosmo Pharmaceuticals Appoints New Chief Financial Officer". Dublin.

Ad hoc announcement pursuant to Art. 53 LR

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016.

Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna’s rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency.

Niall will transition to a strategic new role as EVP – Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo’s corporate governance framework and driving the Company’s mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall’s leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company’s long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.

Giovanni Di Napoli, CEO of Cosmo, commented: “Svetlana’s appointment marks a pivotal step in Cosmo’s global expansion strategy. With her extensive experience in fast-growing, global organizations, she will be an invaluable asset in guiding our financial strategy, driving performance, and supporting our mission to enhance our presence in international markets. We are excited to have her expertise as we take Cosmo to the next level.”

Giovanni added: “At the same time, we want to extend our heartfelt gratitude to Niall for his outstanding service as CFO over the past eight years. Niall has been instrumental in shaping Cosmo’s financial foundation, and we are thrilled that he will continue to bring his vast experience and strategic insight to our corporate governance and ESG efforts. His leadership in establishing strong governance frameworks and driving sustainability initiatives will be key in reinforcing the commitment of our Company to responsible growth and long-term value.”

Svetlana Sigalova stated: “I am truly honored to join Cosmo’s dynamic team and excited to work alongside the Management Team and employees to support the company’s ambitious growth plans. It is a privilege to contribute to such an innovative organization with solid revenue drivers and promising R&D projects. I look forward to leveraging my experience to help drive Cosmo’s financial excellence and global expansion.”

About Cosmo

Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 300 employees, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.

Upcoming Calendar of Events

UBS Global Healthcare Conference, California November 11-14, 2024

Jefferies London Healthcare Conference, London November 19-21, 2024

For further information, please contact

Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
[email protected]

Disclaimer

Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.